Provided by Tiger Trade Technology Pte. Ltd.

CMS

12.870
-0.400-3.01%
Volume:3.70M
Turnover:47.90M
Market Cap:31.40B
PE:18.49
High:13.370
Open:13.250
Low:12.780
Close:13.270
52wk High:15.630
52wk Low:6.649
Shares:2.44B
HK Float Shares:2.44B
Volume Ratio:0.91
T/O Rate:0.15%
Dividend:0.33
Dividend Rate:2.57%
EPS(LYR):0.696
ROE:8.50%
ROA:5.30%
PB:1.60
PE(LYR):18.49
PS:3.38

Loading ...

China Medical System says China approves Desidustat tablets for CKD anaemia

Reuters
·
Mar 13

CMS Subsidiary Dermavon Records First China Prescriptions for Lumirix Vitiligo Cream

Reuters
·
Mar 13

CMS Secures Regulatory Clearance for Clinical Trials of INHBE Small RNA Drug CMS-D008 Targeting Overweight and Obesity

Deep News
·
Mar 06

China Medical System Holdings Limited Approval of Drug Clinical Trials for Overweight/Obesity Indication of Self-Developed Drug CMS-D008

THOMSON REUTERS
·
Mar 04

CMS (00867) Schedules Board Meeting for 16 March 2026 to Review 2025 Annual Results

Bulletin Express
·
Mar 04

CMS (00867) Obtains NMPA Approval for Clinical Trials of INHBE-Targeting Drug CMS-D008 for Overweight/Obesity

Bulletin Express
·
Mar 04

CMS Pharmaceutical's Innovative siRNA Drug CMS-D008 Receives Clinical Trial Approval for Overweight/Obesity Indication

Stock News
·
Mar 04

China Medical System Holdings - CMS-D008 Receives Drug Clinical Trial Approval From Nmpa

THOMSON REUTERS
·
Mar 04

China Medical System Holdings wins NMPA approval to start CMS-D008 obesity clinical trials

Reuters
·
Mar 04

China Medical System (00867) Releases February 2026 Monthly Return

Bulletin Express
·
Mar 02

CMS Receives Initial "Buy" Rating from Cinda Securities as Innovation-Driven Transformation Drives Long-Term Growth

Stock News
·
Feb 25

BRIEF-CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream Accepted

Reuters
·
Feb 24

CMS (867.HK/8a8.SG): Nda for Additional Indication Atopic Dermatitis (Ad) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China

THOMSON REUTERS
·
Feb 24

China Medical System Holdings - Review Timeline Shortened From 200 Days to 130 Days

THOMSON REUTERS
·
Feb 24

CMS Announces Priority Review Acceptance for Ruxolitinib Phosphate Cream in China for Atopic Dermatitis

Bulletin Express
·
Feb 24

China Medical System Holdings Limited Nda for Additional Indication Ad for Ruxolitinib Cream Accepted and Granted Priority Review in China

THOMSON REUTERS
·
Feb 24

CMS Receives NMPA Acceptance and Priority Review for Ruxolitinib Cream's Atopic Dermatitis Application

Stock News
·
Feb 24

China Medical System - Gets Acceptance From China's Nmpa for New Drug Application of Ruxolitinib Phosphate Cream for Treatment of Atopic Dermatitis

THOMSON REUTERS
·
Feb 24

China Medical System unit Dermavon wins China priority review for ruxolitinib cream in atopic dermatitis

Reuters
·
Feb 24

Assessing China Medical System Holdings (SEHK:867) Valuation After New Lidoderm Rights And AI Drug Discovery Deal

Simply Wall St.
·
Feb 24